Correspondence | Published:

Drug targeting in Acanthamoeba keratitis: rational of using drugs that are already approved for ocular use in non-keratitis indications

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Schlander Michael, Holm Søren, Nord Erik, Richardson Jeff, Garattini Silvio, Kolominsky-Rabas Peter, et al. 8th European Conference on Rare Diseases & Orphan Products (ECRD 2016). Orphanet J Rare Dis. 2016;11(Suppl 1):1–9.

  2. 2.

    Seal DV. Acanthamoeba keratitis update-incidence, molecular epidemiology and new drugs for treatment. Eye (Lond). 2003;17:893–905.

  3. 3.

    Baig AM, Ahmad HR. (2017). Evidence of a M1-Muscarinic GPCR homolog in unicellular eukaryotes: featuring Acanthamoeba spp bioinformatics 3D-modelling and experimentations. J Recept Signal Transduct Res. 2017;7:1–9.

  4. 4.

    Agahan AL, Lim RB, Valenton MJ. Successful treatment of Acanthamoeba keratitis without anti-amoebic agents. Ann Acad Med Singap. 2009;38:175–17.

  5. 5.

    Baig AM, Hareem Z, Khan NA. Recommendations for the management of Acanthamoeba keratitis. J Med Microbiol. 2014;

  6. 6.

    Sifaoui I, Reyes-Batlle M, López-Arencibia A, Chiboub O, Rodríguez-Martín J, Rocha-Cabrera P et al. Toxic effects of selected proprietary dry eye drops on Acanthamoeba. Sci Rep. 2018;8:8520.

Download references

Author information

Correspondence to Abdul Mannan Baig.

Ethics declarations

Conflict of interest

The author declares that he has no conflict of interest. The author has not received any assistance in writing this paper and has no associations with the pharmaceutical companies. This project has been partly funded by Aga Khan University Pakistan.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Further reading

Fig. 1
Fig. 2